Teva Pharmaceutical Industries Limited (TEVA) Lifted to “Sell” at BidaskClub

BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a strong sell rating to a sell rating in a report issued on Tuesday, June 13th.

A number of other analysts have also recently commented on TEVA. Zacks Investment Research upgraded Teva Pharmaceutical Industries Limited from a sell rating to a hold rating in a research report on Monday, April 17th. Deutsche Bank AG cut their target price on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating on the stock in a research report on Friday, May 12th. Vetr raised Teva Pharmaceutical Industries Limited from a buy rating to a strong-buy rating and set a $37.48 price target on the stock in a report on Tuesday, April 11th. Cowen and Company reissued an outperform rating and set a $50.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday, April 4th. Finally, Citigroup Inc. lowered their price target on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a buy rating on the stock in a report on Tuesday, April 25th. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $43.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.13% during midday trading on Tuesday, hitting $31.37. 4,563,629 shares of the stock were exchanged. The company has a market capitalization of $31.87 billion, a P/E ratio of 402.18 and a beta of 0.49. The company’s 50 day moving average is $30.18 and its 200 day moving average is $33.11. Teva Pharmaceutical Industries Limited has a 1-year low of $27.59 and a 1-year high of $56.44.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The company had revenue of $5.63 billion for the quarter, compared to analysts’ expectations of $5.69 billion. During the same period last year, the firm earned $1.20 earnings per share. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 17.0% on a year-over-year basis. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.79 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://sportsperspectives.com/2017/06/20/teva-pharmaceutical-industries-limited-teva-upgraded-by-bidaskclub-to-sell-updated.html.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 22nd. Investors of record on Monday, June 5th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, June 1st. This represents a $1.36 dividend on an annualized basis and a yield of 4.34%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is 5,802.90%.

A number of hedge funds have recently made changes to their positions in TEVA. Jacobi Capital Management LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 33.8% in the first quarter. Jacobi Capital Management LLC now owns 5,261 shares of the company’s stock worth $168,000 after buying an additional 1,328 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $16,321,000. Achmea Investment Management B.V. acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $688,000. Bank of Nova Scotia acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $391,000. Finally, First City Capital Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. First City Capital Management Inc. now owns 26,670 shares of the company’s stock worth $856,000 after buying an additional 100 shares during the period. 56.26% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply